Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-08-07

Clinical Trial Update: A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging trial of AeroFact in premature infants with respiratory distress syndrome has been completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AeroFact

Snippet

Sponsor: Aerogen Pharma Limited | Conditions: Respiratory Distress Syndrome in Premature Infant | Phase 2 | Status: COMPLETED | Results posted: 2025-08-07